Using large data to study outcomes in cirrhosis?Comorbid conditions in cirrhosis:
1⃣ are common - 44% with psych/SUD
2⃣ impact mortality
3⃣ are best measured with hospital frailty risk score
doi.org/10.1016/j.jhep…
@swethap9 Eric S Orman MD MSCR Lauren Nephew MD, MSCE Naga Chalasani Indiana University Gastroenterology and Hepatology

Nomenclature update to AASLD practice guidance out today! #LiverTwitter AASLD Fasiha Kanwal Rohit Loomba Elliot Tapper Mazen Noureddin, MD, MHSc Juan Pablo (JP) Arab, MD  journals.lww.com/hep/citation/9…

This study shows that 'moderate alcohol-associated hepatitis' (i.e. MELD <21):

🔸It's not a benign condition: 12% mortality at 90 days.
🔸Should not be treated with corticosteroids.

We need trials to improve their outcome !

shorturl.at/lxzN0 #livertwitter #MedTwitter

Congratulations to our own⭐️Howard T. Lee MD for publishing this🔥important article in The Lancet Gastroenterology & Hepatology re liver #transplant for 🏳️‍⚧️🏳️‍🌈 #LGBTQ + people as the first author!

It is 🆓to read for 50 days, so download it ASAP👇
authors.elsevier.com/a/1hvNc8nByr8u…

#LiverTwitter #DEI #TransplantTwitter

Thank you⭐️Naga Chalasani Indiana University Gastroenterology and Hepatology for such an excellent presentation bout #PNPLA3 and #MASLD at BCM Gastroenterology grand round!

Check out the🔥summary👇

#LiverTwitter 🤔Do you check #PNPLA3 on your #MASLD patients (if 💴 is not a concern)? Share your thoughts with us

The guru of NALD (MAFLD)
Naga Chalasani.
Always a treat to hear his talks and continue to learn for him. Thanks Naga Chalasani Indiana University Gastroenterology and Hepatology for visiting BCM Gastroenterology. Fasiha Kanwal

Must read by Giuseppe Cullaro. NSBB maybe harmful in CTP C and those with severe ascites. Do we need a RCT in CTP C patients to settle the debate? Salvatore Piano Ruben Hernaez

Dear GI Fellows, are you looking for a board review course that
✅Cover core/interventional GI, liver, IBD, motility
✅All⭐️faculty
✅virtual option
✅🆓to register!

Look no further! Sign up for BCM Gastroenterology board review course this weekend (9/21-9/23)
bcm.edu/departments/me……

#Livertwitter A most dreaded complication of #cirrhosis is refractory hepatic hydrothorax (RH)
Our paper in HEPATOLOGY Journal
RH ⬇️prognosis >Refr ascites
☝️RH -> ⬆️liver relatd death- HR 4.63
✌️⬆️Mortality ->⬆️# thoracentesis
Death in RH @ ⬇️MELD-Na than RA
pubmed.ncbi.nlm.nih.gov/37625139

🔥How to screen🧐for liver fibrosis in general population?

🆕LiverRisk score:
✅predicts liver fibrosis in >14,000 subjects
✅predicts liver related events in >400,000 subjects
✅outperforms FIB-4 and APRI

Massive effort of LiverScreen H2020 in The Lancet

authors.elsevier.com/c/1hZE5V-4XL36T

Prognostic significance of acute kidney injury stage 1B in hospitalized patients w/ #cirrhosis : A US nationwide study

AKI stage-1B =⬆️risk for 90-day mortality, AKI-progression &⬇️probability of AKI-recovery vs AKI stage-1A

journals.lww.com/lt/Abstract/99…

#livertwitter #AKI #nephrology

Look at that cost for AKI!
Giuseppe Cullaro HRS Harmony Global Aki Salvatore Piano

Proud to be part of this work lead by Eric Orman, Naga Chalasani Indiana University Gastroenterology and Hepatology.

See our study⬇️

Bottom line:

✅1B : ⬆️progression, ⬇️recovery, ⬆️ death vs 1A

✅ This data could guide initial management decisions for AKI in cirrhosis.

Should we avoid albumin in stage 1A completely?

Giuseppe Cullaro Salvatore Piano Andrew Allegretti BCM Gastroenterology Liver Transplantation Journal (LTxJournal)

Another important article to read on DILI by whom I consider the “guru of DILI” Naga Chalasani

Plasma exchange for acute & acute on chronic liver failure: A systematic review & Meta-Analysis
by @kavishpatidar11 et al

journals.lww.com/lt/Abstract/99…

#livertwitter #ACLF